Trial Profile
Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Ziconotide (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms ZIDON
- 23 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 23 Mar 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.
- 03 Mar 2021 Planned End Date changed from 1 Jul 2018 to 1 Dec 2022.